This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Amy L. Aiello, MD; Alfredo A. Sadun, MD; Steven E. Feldon, MD
Los Angeles, Calif

Arch Ophthalmol. 1993;111(12):1602-1603.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

McHenry and Spoor suggest that the presence of optic nerve sheath fluid is of primary importance in predicting whether or not progressive AION is likely to improve following optic nerve sheath fenestration. On the basis of their results,¹ they propose that the appropriate randomized clinical trial should be limited to those patients with demonstrable fluid in the optic nerve sheath, as documented with ultrasonography.

The basis for the ongoing National Eye Institute-funded Ischemic Optic Neuropathy Decompression Trial (IONDT) is that surgery may benefit both progressive and nonprogressive forms of AION. Although patients with progressive AION are eligible for the study, there will not be sufficient numbers of patients recruited to detect a difference in outcome between these patients and those with nonprogressive disease. To exclude patients whose AION is not progressive, who have no detectable optic nerve sheath fluid, or who have both would make a prospective, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?